Samuel Stevens, Common Sense Oncology Fellow in Cancer Policy at Queen’s University and VMO – Medical Oncologist at NSW Health, shared a post on LinkedIn:
“Australia’s recent tumor agnostic immunotherapy approvals are an experiment in drug policy that aims to improve equity of access but requires government, industry, clinicians and patients to shoulder considerable risks. Does Australia have the initiative and data infrastructure to convert this bold decision into evidence that clinicians and health systems can use? Read our comment in Nature Portfolio Clinical Reviews Oncology here.”
Title: Realizing the benefits of tumour-agnostic access requires a national health learning system
Authors: Samuel Stevens, Deme Karikios
Read the comment here.
Other articles about Immunotherapy on OncoDaily.